Figure 7.

Fibrin-specific nanogel. a) The design of fibrin-specific nanogel. b) Drug-loaded nanoparticles combat MI, which occurs due to a fibrin-rich thrombus blocking blood flow and creating ischemic myocardium, and subsequent cardiac fibrosis upon reperfusion. Drug-loaded FSNs will bind to fibrin at the infarct site, release a fibrinolytic drug, and release a small-molecule cell contractility-inhibitor to mitigate cardiac fibrosis due to reperfusion injury. c) Core and C/S nanogel design. d) Size characterization (n = ≥30 per group). e) Nanosight particle tracking for hydrodynamic diameter measurements. f) Dry AFM images on a glass surface. Reproduced with permission.^[65] Copyright 2018, American Chemical Society.